Search Within

Larry Norton

  1. "Epidemiology and Biostatistics"
Formats
  1. Meeting Abstract (108)
  2. Journal Article (92)
Groups
  1. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (200)
  2. Breast Medicine Service (200)
  3. Department of Medicine (200)
  4. Epidemiology and Biostatistics (200)
  5. Solid Tumor Oncology Division (200)
  6. Biostatistics Service (183)

More Groups

People
  1. Clifford Hudis (135)
  2. Sujata Patil (97)
  3. Chau Dang (50)
  4. Katherine Panageas (47)
  5. Maura Dickler (40)
  6. Monica Fornier (38)

More People

Years
  1. 2024 (3)
  2. 2023 (5)
  3. 2022 (6)
  4. 2021 (2)
  5. 2020 (11)
  6. 2019 (9)

More Years

Publications
  1. Journal of Clinical Oncology (57)
  2. Cancer Research (33)
  3. Breast Cancer Research and Treatment (23)
  4. Clinical Cancer Research (15)
  5. Cancer (8)
  6. Clinical Breast Cancer (7)

More Publications

Publishers
  1. American Society of Clinical Oncology (58)
  2. American Association for Cancer Research (51)
  3. Springer (24)
  4. Nature Publishing Group (12)
  5. Oxford University Press (10)
  6. Wiley Blackwell (9)

More Publishers

Results (200)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Clinical, morphologic and immunophenotypic characteristics of primary breast carcinomas (BC) with brain metastases (BM)
    Meeting Abstract

    Brogi, E.; Murray, M. P.; Patil, S.; Akram, M.; Nehhozina, T.; Norton, L.; Seidman, A.; Tan, L. K.
    Laboratory Investigation (2007)

    Fulltext@MSK | Save
  • Immunization of high-risk breast cancer patients with clustered sTn-KLH conjugate plus the immunologic adjuvant QS-21
    Journal Article

    Gilewski, T. A.; Ragupathi, G.; Dickler, M.; Powell, S.; Bhuta, S.; Panageas, K.; Koganty, R. R.; Chin-Eng, J.; Hudis, C.; Norton, L.; more...
    Clinical Cancer Research (2007)

    Fulltext@MSK | Save
  • Increased dose density is feasible: A pilot study of adjuvant epirubicin and cyclophosphamide followed by paclitaxel, at 10- or 11-day intervals with filgrastim support in women with breast cancer
    Journal Article

    Fornier, M. N.; Seidman, A. D.; Lake, D.; D'Andrea, G.; Bromberg, J.; Robson, M.; Van Poznak, C.; Panageas, K. S.; Atienza, M.; Norton, L.; more...
    Clinical Cancer Research (2007)

    Fulltext@MSK | Save
  • Optimizing chemotherapy administration: A phase I study of biweekly capecitabine dose and schedule based on Norton-Simon mathematical modeling
    Meeting Abstract

    Traina, T. A.; Theodoulou, M.; Dugan, U.; Feigin, K.; Panageas, K.; Hodgman, E.; Norton, L.; Hudis, C. A.
    Breast Cancer Research and Treatment (2006)

    Fulltext@MSK | Save
  • Letrozole (L) with bevacizumab (B) is feasible in patients (pts) with hormone receptor-positive metastatic breast cancer (MBC)
    Meeting Abstract

    Traina, T. A.; Rugo, H.; Caravelli, J.; Yeh, B.; Panageas, K.; Bruckner, J.; Norton, L.; Park, J.; Hudis, C.; Dickler, M.
    Journal of Clinical Oncology (2006)

    Fulltext@MSK | Save
  • A pilot study of growth factor (GF) omission during paclitaxel (T) for women with early breast carcinoma (BC)
    Meeting Abstract

    Sugarman, S. M.; Wasserheit, C.; Hodgman, E.; Coglianese, M. E.; D'alessandro, A.; Fornier, M.; Troso-Sandoval, T.; D'Andrea, G.; Drullinsky, P.; Lake, D.; more...
    Breast Cancer Research and Treatment (2006)

    Fulltext@MSK | Save
  • Expression of osteoprotegerin (OPG), TNF related apoptosis inducing ligand (TRAIL), and receptor activator of nuclear factor κB ligand (RANKL) in human breast tumours
    Journal Article

    Van Poznak, C.; Cross, S. S.; Saggese, M.; Hudis, C.; Panageas, K. S.; Norton, L.; Coleman, R. E.; Holen, I.
    Journal of Clinical Pathology (2006)

    Fulltext@MSK | Save
  • Pharmacokinetics and toxicity of weekly docetaxel in older patients
    Journal Article

    Hurria, A.; Fleming, M. T.; Baker, S. D.; Kelly, Wm K.; Cutchall, K.; Panageas, K.; Caravelli, J.; Yeung, H.; Kris, M. G.; Gomez, J.; more...
    Clinical Cancer Research (2006)

    Fulltext@MSK | Save
  • A phase II trial of letrozole in combination with bevacizumab, an anti-VEGF antibody, in patients with hormone receptor-positive metastatic breast cancer
    Meeting Abstract

    Traina, T. A.; Dickler, M. N.; Caravelli, J. F.; Yeh, B. M.; Brogi, E.; Panageas, K.; Flores, S. A.; Norton, L.; Park, J.; Hudis, C.; more...
    Breast Cancer Research and Treatment (2005)

    Fulltext@MSK | Save
  • A feasibility study of an aromatase inhibitor (Al), letrozole (L) and the antibody to vascular endothelial growth factor (VEGF), bevacizurnab (B), in patients (pts) with hormone receptor-positive metastatic breast cancer (MBC)
    Meeting Abstract

    Traina, T. A.; Dickler, M. N.; Caravelli, J. F.; Yeh, B. M.; Brogi, E.; Panageas, K.; Flores, S. A.; Norton, L.; Hudis, C.; Rugo, H.
    Journal of Clinical Oncology (2005)

    Fulltext@MSK | Save